Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL465908 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL9625167 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL992285 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL1832445 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL292514 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL3199266 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL7090995 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL4784041 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL2031974 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL948 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2548872-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | ALDH1A1 2914/4885TSHR 567/4885HSD17B10 152/4885 |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | ALDH1A1 2914/4885TSHR 567/4885HSD17B10 152/4885 |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | ALDH1A1 1259/4885TSHR 198/4885HSD17B10 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.